Published in:
Open Access
01-12-2018 | Case report
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
Authors:
Lishu Yang, Lizhu Liu, Bo Han, Wei Han, Meng Zhao
Published in:
BMC Cancer
|
Issue 1/2018
Login to get access
Abstract
Background
Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer.
Case presentation
Herein, we report a patient with advanced angiosarcoma, who received apatinib at a daily dose of 250 to 725 mg, resulting in a partial response for three months, which may be related to Kinase Insert Domain Receptor (KDR) gene amplification.
Conclusion
Our experience reported here indicated that apatinib may be a useful therapeutic option for treatment of patients with advanced angiosarcoma.